Assessment of preeclampsia using assays for free and dissociated placental growth factor

Abstract

Described herein are methods, compositions, kits, and systems for detecting free and bound PlGF, and using detection of such species to distinguish between pregnant women with or without preeclampsia or related conditions.

1 .- 96 . (canceled) 
     
     
         97 . A kit for assessing a risk of preeclampsia or ruling out preeclampsia in a pregnant female subject, the kit comprising:
 (a) an agent or apparatus for dissociating placental growth factor (PLGF) from a PLGF complex with another protein; and   (b) at least one probe for specific binding to placental growth factor (PLGF).   
     
     
         98 . The method of  claim 97 , wherein the kit is designed to measure the levels of no more than 10 different proteins. 
     
     
         99 . The kit of  claim 98 , wherein the kit is further designed to measure the levels of at least one of sFLT, Endoglin, KIM-1, and FGF21. 
     
     
         100 . The kit of  claim 99 , wherein the kit further comprises at least one probe for specific binding to at least one of sFLT, Endoglin, KIM-1, and FGF21. 
     
     
         101 . The kit of  claim 98 , wherein the kit is an enzyme-linked immunosorbent assay kit. 
     
     
         102 . The kit of  claim 97 , the at least one probe is attached to a substrate. 
     
     
         103 . The kit of  claim 98 , wherein the kit is for a lateral flow immunoassay. 
     
     
         104 . The kit of  claim 97 , further comprising a collection tube for collecting a biological sample from the pregnant female subject. 
     
     
         105 . The kit of  claim 104 , where the collection tube is suitable for collection of serum or plasma. 
     
     
         106 . The kit of  claim 97 , wherein the at least one probe for specific binding to PLGF comprises an antibody or antigen-binding fragment. 
     
     
         107 . The kit of  claim 100 , wherein the least one probe for specific binding to at least one of sFLT, Endoglin, KIM-1, and FGF21 comprises an antibody or antigen-binding fragment. 
     
     
         108 . The kit of  claim 97 , further comprising a microwell or multiwell plate. 
     
     
         109 . The kit of  claim 108 , wherein the microwell or multiwell plate comprises at least one well with the at least one probe for specific binding to PLGF. 
     
     
         110 . The kit of  claim 97 , wherein the kit comprises the agent for dissociating placental growth factor from the PLGF complex with another protein. 
     
     
         111 . The kit of  claim 110 , wherein the agent for dissociating placental growth factor from the PLGF complex with another protein is selected from a surfactant, a detergent, a chaotropic agent, a PLGF-binding protein, and an sFLT-binding protein. 
     
     
         112 . The kit of  claim 110 , wherein the agent for dissociating placental growth factor from the PLGF complex with another protein is a surfactant. 
     
     
         113 . The kit of  claim 110 , wherein the agent for dissociating placental growth factor from the PLGF complex with another protein is a detergent. 
     
     
         114 . The kit of  claim 110 , wherein the agent for dissociating placental growth factor from the PLGF complex with another protein is a chaotropic agent. 
     
     
         115 . The kit of  claim 110 , wherein the agent for dissociating placental growth factor from the PLGF complex with another protein is a pH adjustment agent. 
     
     
         116 . The kit of  claim 97 , wherein the kit comprises the apparatus for dissociating placental growth factor from the PLGF complex with another protein. 
     
     
         117 . The kit of  claim 116 , wherein the apparatus comprises a heating element.